Acral Melanoma Clinical Trials

5 recruiting

Acral Melanoma Trials at a Glance

7 actively recruiting trials for acral melanoma are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Atlanta, Beijing, and Beijing. Lead sponsors running acral melanoma studies include Peking University Cancer Hospital & Institute, Anusha Kalbasi, and Di Wu.

Browse acral melanoma trials by phase

Treatments under study

About Acral Melanoma Clinical Trials

Looking for clinical trials for Acral Melanoma? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Acral Melanoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Acral Melanoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Breast CancerHead and Neck Squamous Cell CarcinomaMetastatic Malignant Solid Neoplasm+14 more
Anusha Kalbasi18 enrolled3 locationsNCT04119024
Recruiting
Phase 1

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Lung Non-Small Cell Carcinoma+22 more
Fred Hutchinson Cancer Center25 enrolled1 locationNCT05098210
Recruiting
Phase 2

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Acral MelanomaMetastatic Cutaneous Melanoma+7 more
Emory University99 enrolled2 locationsNCT07155317
Recruiting
Phase 2

Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial

Acral MelanomaMelanoma of SkinStage II Melanoma
Fudan University58 enrolled4 locationsNCT06965231
Recruiting
Phase 2

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

MelanomaAcral MelanomaNeoadjuvant+4 more
Peking University Cancer Hospital & Institute60 enrolled1 locationNCT05512481
Recruiting
Phase 3

Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

Acral Melanoma
Peking University Cancer Hospital & Institute140 enrolled1 locationNCT05789043
Recruiting
Phase 2

Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma

Acral Melanoma
Di Wu40 enrolled1 locationNCT04331093